| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
22,005 |
21,682 |
$3.59M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
4,659 |
4,613 |
$1.13M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
2,175 |
2,136 |
$727K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
2,495 |
2,446 |
$322K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
1,323 |
1,322 |
$112K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,047 |
1,033 |
$90K |
| 36415 |
Collection of venous blood by venipuncture |
7,949 |
7,552 |
$63K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
337 |
337 |
$44K |
| 80053 |
Comprehensive metabolic panel |
4,069 |
3,912 |
$37K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
5,456 |
5,133 |
$35K |
| 95813 |
|
133 |
133 |
$30K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
345 |
343 |
$26K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
616 |
600 |
$24K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
496 |
447 |
$22K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
147 |
147 |
$20K |
| 87400 |
|
825 |
824 |
$20K |
| 71045 |
Radiologic examination, chest; single view |
1,066 |
1,054 |
$14K |
| 69436 |
Tympanostomy (requiring insertion of ventilating tube), general anesthesia |
25 |
25 |
$13K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
252 |
251 |
$12K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
55 |
55 |
$9K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
1,283 |
1,185 |
$7K |
| 81001 |
|
2,442 |
2,330 |
$7K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,167 |
1,129 |
$6K |
| 81025 |
|
840 |
827 |
$6K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
97 |
94 |
$6K |
| 71046 |
Radiologic examination, chest; 2 views |
353 |
352 |
$6K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
100 |
98 |
$5K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
465 |
458 |
$5K |
| 84484 |
|
369 |
327 |
$4K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
28 |
28 |
$4K |
| 85027 |
|
662 |
646 |
$4K |
| 81003 |
|
1,794 |
1,764 |
$3K |
| 83690 |
|
410 |
402 |
$2K |
| 71250 |
|
53 |
53 |
$2K |
| 87420 |
|
156 |
155 |
$2K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
18 |
18 |
$2K |
| 87430 |
|
115 |
115 |
$2K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
12 |
12 |
$2K |
| 94060 |
|
86 |
86 |
$2K |
| 76801 |
|
14 |
14 |
$768.69 |
| 83605 |
|
76 |
64 |
$751.17 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
105 |
104 |
$745.97 |
| 87070 |
|
85 |
85 |
$621.62 |
| 88304 |
|
25 |
25 |
$551.40 |
| 70450 |
Computed tomography, head or brain; without contrast material |
12 |
12 |
$549.50 |
| 82550 |
|
97 |
97 |
$544.26 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
40 |
39 |
$520.52 |
| 74018 |
|
15 |
15 |
$273.60 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
61 |
55 |
$271.44 |
| 85610 |
|
57 |
56 |
$213.92 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
12 |
12 |
$86.09 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
55 |
55 |
$40.58 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
33 |
25 |
$13.72 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
119 |
119 |
$5.92 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
175 |
172 |
$1.39 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
27 |
25 |
$0.00 |
| J7050 |
Infusion, normal saline solution, 250 cc |
88 |
74 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
27 |
26 |
$0.00 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
13 |
13 |
$0.00 |
| 99152 |
|
13 |
13 |
$0.00 |